COGNITION THERAPEUTICS INC (CGTX) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-07

Key Insights

Cognition Therapeutics announced Q1 2026 financial results on May 7, 2026, with detailed results furnished via press release in Exhibit 99.1, though the specific financial metrics are not visible in the 8-K filing itself.
The company is an emerging growth company on Nasdaq (CGTX) and has elected to use the standard transition period for new accounting standards, indicating compliance with standard regulatory frameworks.
Lisa Ricciardi serves as President and CEO, signing the 8-K filing, confirming stable leadership at the time of earnings announcement.

Want the newest filings?

This analysis covers the filing from 2026-05-07. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-03-26

Cognition Therapeutics announced its financial results for the year ended December 31, 2025, indicating the company's performance during the previous fiscal year.
The company has provided an investor presentation that may be used in discussions with investors, analysts, and other parties, which could offer additional insights into the company's operations and strategy.
Cognition Therapeutics is an emerging growth company, which may provide it with more flexibility in complying with financial reporting standards.

Filed: 2026-03-02

Cognition Therapeutics plans to advance the development of zervimesine for the treatment of dementia with Lewy bodies psychosis, indicating progress in their pipeline.
The company's stock is traded on the Nasdaq stock exchange under the ticker symbol CGTX.
Cognition Therapeutics is an emerging growth company, which means it may take advantage of certain exemptions from financial reporting and other requirements.

Filed: 2026-01-27

Cognition Therapeutics announced the completion of a Tye C meeting with the FDA for its dementia with Lewy bodies drug candidate zervimesine, indicating progress in the regulatory process.
The company is an emerging growth pharmaceutical firm, which may mean it has greater flexibility in financial reporting and accounting standards compared to more established firms.
No other material events or changes were reported in the 8-K filing, suggesting the company's operations and leadership are stable at this time.

Other reports for COGNITION THERAPEUTICS INC

Quarterly Report Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.